1. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW (1983) Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxy daunorubicin in patients with advanced cancer. Cancer Res 43: 6096?6101
2. Casazza AM, Barbieri B, Fumagalli A, Geroni MC (1983) Biologic activity of 4-demethoxy-13-dihydrodaunorubicin. Proc Am Assoc Cancer Res 24: 251
3. Cummings J, Milroy R, Banham SW, Kaye SB (1987) Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography. Cancer Chemother Pharmacol 19: 296?300
4. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW (1985) Phase I and II clinical and pharmacological study of 4-demethoxy daunorubicin (idarubicin) in adult patients with acute leukaemia. Cancer Res 45: 1408?1412
5. Ganzina F, Pacciarini MA, Di Pietro N (1986) Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Invest New Drugs 4: 85?105